Actively Recruiting
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of FB102 Given Intravenously to Adults With Severe to Very Severe Alopecia Areata
Led by Forte Biosciences, Inc. · Updated on 2025-11-20
32
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of FB102 in adults with severe to very severe alopecia areata, a condition causing significant hair loss. This randomized, double-blind, placebo-controlled Phase 1 study aims to better understand how FB102 works compared to a placebo in this patient group. Up to 32 participants will be randomly assigned in a 3 to 1 ratio to receive either FB102 or a matching placebo. Both treatments are given intravenously. The study will monitor participants over several weeks, assessing safety and changes in hair loss severity. Participants will be involved in the study for up to 36 weeks after their first dose. During this time, they will undergo regular evaluations including tracking treatment-related side effects and measuring changes in hair loss using the Severity of Alopecia Tool SALT score. Researchers will carefully monitor safety and treatment responses throughout the study.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Research Team
S
Support Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
